Abstract Object: The pathogenesis of carotid artery stenosis (CAS) as well as the mechanisms underlying the different localisation of the atherosclerotic lesions remains poorly understood. We used microarray technology to identify novel systemic mediators that could contribute to CAS pathogenesis.
Carotid artery disease is a major cause of ischaemic stroke, 1 and cerebrovascular disease is one of the main causes of death and disability in developed countries. 2 Atherosclerosis is a chronic immune-inflammatory disease of the arterial wall, where both innate and adaptive immunologic and inflammatory mechanisms are involved. 3 The fine mechanisms underlying carotid artery stenosis (CAS) pathogenesis as well as the localisation of the atherosclerotic lesions in different districts of the arterial tree remain poorly understood.
Several genomic approaches have been applied to understand the multifactorial nature and different localisation of atherosclerosis: these include genome-wide and candidate gene association, as well as transcriptome and proteome studies. 4 Besides traditional cardiovascular risk factors, there is a current interest in the identification of novel molecular risk markers of atherogenesis and atherothrombosis.
A large number of expression profiling studies has been conducted over the past few years to investigate the molecular pathways involved in the onset and progression of atherosclerosis in CAS as well as other arteries' diseases. 5 Most studies compared whole atherosclerotic plaques or specific plaque regions to non-diseased arteries/ regions. Transcript levels were analysed to study either the early phases of atherosclerosis or the progression from stable to ruptured lesions. 5 Few data are available on the global transcriptomic profile at systemic level.
In this study, we used a gene-expression profiling approach by using a two-colour microarray technology on peripheral blood to find possible mediators/markers, at systemic level, of CAS. In fact, blood is an easy specimen to obtain that could represent a valuable resource to translate results in diagnosis and prognosis processes. Moreover, blood is a fitting surrogate for atherosclerotic tissue, because it contains the inflammatory cells that are involved in its pathogenesis. 6 Therefore, our study aimed to: (1) identify novel mediators/markers of CAS at the systemic level by studying the gene-expression profile of peripheral blood of patients with respect to control subjects; (2) characterise common and peculiar alterations of the gene-expression profile of CAS with respect to another atherosclerotic disease, with a different localisation of the lesions, abdominal aortic aneurysm (AAA), previously studied by our group. 7 
Materials and Methods

Subjects
The study group included 50 patients, undergoing carotid endarterectomy for severe stenosis (>70%) of the extracranial carotid artery, referred to the Vascular Surgery Department (University of Florence). All the patients were asymptomatic. Carotid stenosis was assessed by duplex scanning and confirmed by angiographic computed tomography and the degree of the stenosis was defined according to the North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria. 8 To assess for the presence of additional atherosclerotic disease, all subjects underwent clinical and diagnostic examinations, clinical cardiology evaluation, electrocardiogram (ECG), echocardiogram and peripheral duplex scanning.
A control group of 50 healthy subjects matched for age and gender were recruited in the same period. The control group had a negative history of vascular diseases. Controls were screened for carotid artery disease.
We used a structured questionnaire to identify symptomfree controls and to exclude subjects, who were suspected of having any form of arterial or venous vascular disease.
In patients and controls, blood was collected after an overnight fast. To avoid stress or conditions that may alter the expression profiles, patients were enrolled during the presurgical visit (1 month/15 days before surgery).
Hypertension, 9 dyslipidaemia 10 and diabetes 11 were defined according to international guidelines (additional information in Supplementary Data). The Local Ethics Committee approved the study, and written informed consent was obtained from all participants.
To compare CAS gene-expression profiles obtained in the present study with those of AAA patients obtained in our previous study, 7 we refer to materials and methods reported in the previous article. To facilitate the comparison of demographic and clinical characteristics, data on CAS patients, AAA patients (previous paper) 7 and healthy subjects (present and previous 7 paper) are reported in Table 1 .
Haematological parameters
Blood samples were taken from all subjects for blood counts (red blood cells (RBC), white blood cells (WBC), haemoglobin (Hb), haematocrit (Hct) and reticulocytes) and for serum erythropoietin (EPO) level measurement. The RBC, WBC and reticulocyte counts, Hb and Hct were evaluated using an automated counter, while EPO was determined by DSL1100 Erythropoietin RIA (Diagnostic Systems Laboratories, TX, USA).
Total RNA preparation
Total RNA was extracted from venous peripheral blood using PAXgene Blood RNA Kit (Qiagen, Germany), and RNA quality and integrity were evaluated by capillary electrophoresis with 2100 Bioanalyzer (Agilent, CA, USA) (additional information in Supplementary Data). Equal aliquots of RNA from 10 CAS patients and 10 age-and gendermatched controls were pooled in four different pools, according to the experimental design reported below.
Experimental design and microarray geneexpression analysis
We performed two different pools for 10 CAS patients (n Z 5 patients in pool A and n Z 5 patients in pool B) and two different pools for 10 healthy subjects (n Z 5 controls in pool C and n Z 5 controls in pool D). Two replicates (dye swap) of the two microarray experiments were made. Microarrays experiments were performed as described in our previous articles. 7, 12 We used arrays representing 14 000 genes (70mer oligonucleotides; Human AROS v1.1, Operon Technologies, CA, USA) (additional information in Supplementary Data).
Image processing and statistical analysis
Scanned images were processed using the GenePix Pro 4.1 software (Axon Instruments, CA, USA). For each microarray, we performed a local intensity-dependent normalisation. 13 Data matrices obtained from the pre-processing procedure were analysed in R environment (http://www. r-project.org). Normalisation procedure was done by Statistical Microarray Analysis (sma) package (http://statwww.berkeley.edu/users/terry/zarray/Software/ smacode.html). Due to the Significance Analysis of Microarray (SAM)-method requirements, we analysed all the transcripts that had at least two values out of four for control and CAS patient pools (analysable transcripts).
Data were then analysed by the SAM algorithm. 14 In SAM analysis, we chose a delta value of 0.8 that allowed us to identify differentially expressed genes with a false discovery rate (FDR) of 2.2%. The full data set is available at ArrayExpress (E-MEXP-2113 in http://www.ebi.ac.uk/ microarray-as/ae/browse.html) (additional information in Supplementary Data).
Gene ontology analysis
We used the biological process ontology by the Gene Ontology (GO) consortium. 15 The mappings were downloaded from ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/ gene2go.gz. Details on GO analysis were reported in our previous articles. 7, 12 Real-time PCR based gene-expression analysis Fourteen differentially expressed genes were selected for validation of microarray analysis using RT-PCR in the subjects included in the pools or in the 40 patients and 40 controls used individually to replicate data obtained by microarray experiments. In the selection, we took care to validate genes with increased and decreased expression in CAS. We performed TaqMan RT-PCR using TaqMan predeveloped assays on an ABI Prism 7900 instrument (Applied Biosystems, CA, USA) to quantify the following genes: haemoglobin alpha 2 (HBA2), haemoglobin epsilon 1 (HBE1), haemoglobin theta 1 (HBQ1), dematin (EPB49), glycophorin c (GYPC ), basigin (BSG), regulator of G-protein signalling 2 (RGS2), major histocompatibility complex, class II, DQ beta 1 (HLA-DQB1), major histocompatibility complex, class II, DP alpha 1 (HLA-DPA1), major histocompatibility complex, class II, DP beta 1 (HLA-DPB1), major histocompatibility complex, class I, B (HLA-B) and low-density lipoprotein receptor-related protein 5 (LRP5). The 'deltaedelta Ct method' was used for comparing relative gene-expression results (PE Applied Biosystems, Perkin Elmer, CA). Expression of target genes was standardized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH ) and displayed as foldchange relative to control RNA used as the calibrator.
Statistical analysis
Statistical analyses were carried out using statistical tests as implemented in SPSS software (version 11.5). All values were expressed as median and range. When comparing groups, statistical significance was determined by using non-parametric ManneWhitney test.
Results
Gene-expression profile by microarray technology of peripheral venous whole blood
Of the 14 000 transcripts represented on our arrays, after data processing and application of the filtering criteria, the analysable transcripts numbered 5084. SAM analysis showed 82 genes differentially expressed in peripheral whole blood of CAS patients compared with controls: 61/82 genes had increased expression and 21/82 genes showed decreased expression in CAS patients ( Table 2 ).
Gene ontology analysis of differentially expressed genes in CAS patients
According to GO analysis, we observed four statistically significant enriched biological processes associated with CAS: 'Major Histocompatibility Complex (MHC) class II (antigen processing and presentation)', 'Oxygen Transport', 'MHC class I (antigen processing and presentation)' and 'Immune Response' (Table 3 ). In Table 3 , differentially expressed genes in CAS patients linked to each biological process term are also reported.
Comparison of gene-expression profiles of CAS and AAA patients
Comparing gene-expression profiles obtained in CAS patients (this article) and in AAA patients (previous article), 7 we found 14 genes differentially expressed in both CAS and AAA (Table 2 and Fig. 1 ). Of these 14 genes, 10 showed an increased expression and four a reduced expression in CAS and AAA patients with respect to the respective controls (Table 2 and Fig. 1) .
By contrast, a larger number of genes showed a distinctive expression signature in CAS or AAA patients, which may therefore serve as specific signatures of disease.
Comparing the statistically significant enriched GO biological processes of CAS (Table 3 ) and AAA patients 7 ('oxygen transport': HBA2, HBD, HBE1, HBQ1; 'positive regulation of protein kinase activity': MAP2K3, PTPRC; and 'lipid metabolic process': ACADS, CIDEA, LRP5, MGLL, ADIPOR1, HSD17B14), we found that the alteration of the 'oxygen transport' is a common feature of the two diseases. On the contrary, the alteration of 'immune response' as well as that of the 'lipid metabolism' seems to be a distinctive signature of the CAS and AAA disease, respectively.
Microarray data validation by RT-PCR
To validate and replicate microarray experimental results, the messengerRNA (mRNA) expression of 14 out of 82 differentially expressed genes in CAS was investigated by RT-PCR. We evaluated these genes in the same pools of patients and controls used for microarray experiments (validation study, Table 4 ). Furthermore, we extended the RT-PCR analysis of these 14 genes in two independent larger populations of CAS patients (n Z 40) and controls (n Z 40) (replication study, Table 4 ). We selected five genes that were associated with GO terms altered only in CAS patients: three transcripts associated to the 'MHC class II (antigen processing and presentation)' and 'immune response' (HLA-DPA1, HLA-DPB1, HLA-DQB1); one transcript associated with 'MHC class I (antigen processing and presentation)' and 'immune response' (HLA-B); and one transcript associated to the 'immune response' (IFIT1).
Moreover, we validated nine genes selected among the 14 genes similarly altered in CAS and AAA patients (previous article) 7 ( Table 2 and Fig. 1 ). These nine genes are involved in 'oxygen transport' (HBA2, HBE1, HBQ1), erythrocyte membrane (EPB49 and GYPC ), B-cell development and function as well as signalling in other white cells and platelets (BTK ), induction of metalloproteinases (BSG), regulation of G-protein signalling (RGS2) and lipid metabolic process (LRP5).
All the mRNA levels of genes detected by RT-PCR on the pools were consistent with the microarray experiment ( Table 4) .
Concerning immune response genes, the replication of microarray data on the larger number of CAS patients and controls confirmed the statistically significant increased expression of HLA-DPA1, HLA-DPB1 and HLA-DQB1 and the significant decreased expression of HLA-B (Table 4) .
RT-PCR analysis showed the significant higher expression of HBQ1, HBE1, EPB49, GYPC and BSG in CAS patients compared with controls. Only the HBA2 gene failed to reach the statistical significance, even if it showed a trend to an increased expression in patients. RGS2 and LRP5 were confirmed to have a significant decreased expression in patients with respect to controls (Table 4 ). In Fig. 2 , we showed the scatter plots of the individual DCt values of the three most significant genes (HLA-B, BSG and RGS2).
Haematological parameters in CAS patients and controls
To investigate the possible mechanisms and/or effects of expression changes in erythrocyte genes, we evaluated some haematological parameters (Table 5) . CAS patients had significantly higher values of WBC and RBC counts, Hct and EPO plasma levels with respect to controls.
Discussion
In this article, we reported the peripheral blood geneexpression profile of CAS patients. Moreover, we identified common molecular pathways sustaining similar pathophysiological processes or novel molecular mechanisms of two important atherosclerotic diseases, CAS and AAA, by integrating systemic gene-expression data of CAS obtained in this study with those of AAA obtained in our previous article. 7 Based on GO classification, we found that CAS patients differentially express a large variety of transcripts involved in immune response, antigen processing and presentation and oxygen transport. Whereas the differential expression of genes involved in oxygen transport and of erythrocyte genes, such as GYPC and EPB49, represents a common feature between CAS and AAA patients, the differential expression of genes involved in immune response and antigen processing and presentation represents a distinctive signature of CAS disease. CAS and AAA patients have common risk factors, but they develop one of these two disorders or both. Gene alterations described in this article could explain, at least in part, this paradox. In CAS, we found an increased expression of genes coding components of the MHC class II antigen processing and presentation process (HLA-DPA1, HLA-DPB1, HLA-DQB1, HLA-DRB1/3/5) and a decreased expression of genes coding components of the MHC class I antigen processing and presentation process (HLA-B, IGKC ). These data confirm an activation of MHC class II molecules involved in the development and activation of CD4þ T helper cell-dependent immune response, and indicate a decreased expression of MHC class I molecules involved in activation of CD8þ T celldependent immune response. The increased expression of DBLN, a gene coding an important adaptor protein that regulates the T-cell activation and immune responses, 16 and the altered expression of the two interferon- regulated genes, IFIT1 (increased) and SOCS6 (decreased), suggests further cytokine signalling pathways to be investigated in CAS.
The increased expression of HLA-DPB1, HLA-DQB1 and HLA-DRB1 was consistent with the gene-expression profiling data obtained in the femoral atherosclerotic lesions of patients with peripheral arterial occlusive disease (PAD). 17 The predominant alteration of the immune system-related genes and pathways observed in CAS and PAD patients, but not in AAA patients, might suggest that up-regulation of immune genes may be a critical signature of the atherosclerotic disease in femoral and carotid arteries. Moreover, several literature data on carotid artery lesions suggest that immune reactions with activation of T lymphocytes are a feature of the disease. 18, 19 Several studies have discussed the role of inflammation as the first step in promoting endothelial dysfunction and progression of atherosclerotic processes. Moreover, the auto-immune response against antigens expressed in the endothelium and the greater prevalence of atherosclerosis in immune-mediated rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus strongly suggest the involvement of auto-immunity in the atherosclerotic process. 3 Several pieces of evidence suggested that atherosclerosis could be caused by an immune reaction against autoantigens such as oxidised low-density lipoprotein (LDL) and heat shock proteins (HSP). 3 Auto-immune mechanisms could also play a significant role in diabetesrelated atherosclerosis. 20 Moreover, numerous studies have demonstrated a pathogenetic relationship between atherosclerosis and micro-organisms (bacteria and viruses) causing chronic infections. 20 Interestingly, the microarray profile highlights 14 genes that might sustain common molecular alterations in CAS and AAA. A large part of these genes, although not all, was also validated by RT-PCR analysis in independent larger population of patients and controls.
In particular, we found the decreased expression of the RGS2 gene, coding one of the regulator proteins of the Gprotein signalling pathway, that could be responsible for, at least in part, the high prevalence of hypertension in AAA and CAS patients. RGS2 was shown to be crucial in the regulation of vascular tone as RGS2 deficiency leads to severe hypertension and prolonged vasoconstriction in animal models. 21 Decrease in mRNA and protein RGS2 levels was shown in cells from hypertensive patients. 22 BSG gene coding basigin or EMMPRIN, a 58-kDa membrane glycoprotein member of the immunoglobulin superfamily, showed an increased expression. This datum demonstrates the increased expression in circulating cells of this inductor of several metalloproteinases (MMPs) and, in particular, of MMP9. This finding suggests that EMMPRIN activation could be a mechanism of monocytes/macrophage MMPs expression induction either at the level of the atherosclerotic lesion or at the systemic level. In fact, previous data showed the up-regulation of EMMPRIN in monocytes isolated from patients with acute myocardial infarction, in atherosclerotic lesions from patients with CAS and in ventricles of heart failure patients. 23, 24 Our data in CAS confirmed the important role of decreased expression of LRP5 previously observed in AAA 7 in which we demonstrated an association between decreased expression levels of LRP5 gene and increased levels of Lp(a), suggesting the potential role of LRP5 in Lp(a) catabolism. Even if we observed decreased expression of LRP5 in both CAS and AAA patients, the alteration of the lipid metabolic process was not observed in CAS patients and seems to be a distinctive signature of the aneurysmal disease. 7 Among common features in CAS and AAA patients, our data strongly indicated the role of the alteration of a large number of erythroblast genes involved in oxygen transport n, number of differentially expressed genes annotated to the GO term; N, number of genes represented on the array annotated to the GO term (the reference gene set is the total number of transcripts spotted in the array); p values were adjusted by using the false discovery rate (FDR) multiple testing correction. Figure 1 Venn diagram showing the comparison between differentially expressed genes in CAS (present paper) and AAA patients. 7 and red cell structure stability. Of particular interest were the increased expressions of HBQ1 and HBE1, which encode the theta and epsilon embryonic haemoglobin chains, respectively, suggesting a switch toward the reactivation of genes not normally expressed in adult humans. The increased expression of haemoglobin genes could represent a secondary response to chronic hypoxia and oxidative stress. In addition, the increased expression of structural erythrocyte genes, such as GYPC, might play a role in the adaptative processes of the red cells to chronic hypoxia and haemodynamic stress. Haematological data are consistent with those obtained by other groups concerning the strong association of high haematocrit and blood viscosity with the severity of carotid atherosclerosis. 25, 26 Due to the evaluation of gene-expression in whole blood, one of the limitations of our study was the variation in number and types of the different cell populations. However, this approach allowed us to search for markers of disease in an easily available specimen for translational studies. Moreover, due to the higher prevalence of traditional cardiovascular risk factors and other clinical manifestations of atherosclerosis in patients (coronary artery disease (CAD), peripheral artery disease (PAD) and chronic obstructive pulmonary disease (COPD)), we cannot confirm that the differentially expressed genes identify biomarkers of CAS versus atherosclerosis. Nevertheless, the comparison of CAS and AAA gene-expression signatures represents an indirect response to this issue. For a large part of genes differentially expressed in whole blood (beyond those commented upon), few data are available on their expression in CAS patients' arterial tissue. Further studies are needed to evaluate this issue and analyse whether these findings reflect the biological changes in the artery itself.
Conclusion
In conclusion, our data identify novel molecular alterations possibly involved in the pathogenesis of CAS. GO analysis identified a statistically significant enrichment in CAS of differentially expressed transcripts involved in immune response and oxygen transport. Whereas alteration of oxygen transport is a common tract of the two localisations (CAS and AAA), alteration of immune response in CAS and of lipid metabolic process in AAA represents distinctive tracts of the two atherosclerotic diseases.
Our study brings to light several novel genes that need a strong effort to better comprehend their involvement in the pathophysiology of CAS and AAA and their possible role as markers of progression or targets for therapeutic intervention.
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